Form 4: UTHR Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $512.12 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jan Malcolm, a Director of United Therapeutics Corp (UTHR), reported a transaction involving the company's common stock.
• On December 23, 2025, 50 shares of common stock were disposed of directly.
• The shares were sold at a price of $512.12 per share.
• Following this transaction, Jan Malcolm beneficially owns 420 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was entered into by the reporting person on September 11, 2025.

Sentiment

Score: 5

Explanation: A director's sale of shares, while pre-planned under a 10b5-1 plan, is generally viewed neutrally to slightly negatively by the market, as it doesn't signal increased confidence. However, the pre-planned nature mitigates strong negative sentiment.

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived as a lack of increased confidence in the company's near-term prospects by some market participants.

Future Outlook

NA

Industry Context

This filing reports an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape, but rather details a specific director's stock activity.

Stakeholder Impact

• Shareholders: May observe the director's sale, but the pre-planned nature under Rule 10b5-1 typically reduces concerns about immediate negative implications for the company's prospects.

Key Dates

Recommendation

The filing reports a routine, pre-planned sale of a small number of shares by a director under a 10b5-1 plan. This transaction does not provide new fundamental information about the company's performance or future prospects that would warrant a change in investment recommendation. The sale is likely for personal financial planning rather than a reflection of company-specific concerns.

Keywords

UNITED THERAPEUTICS, UTHR, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Director Transaction